Cantrixil

About Vivesto

Vivesto is a publicly traded Swedish biotech focused on developing novel small molecule drugs for high-need oncology indications in humans and animals. Its strategy centers on advancing a lean pipeline—including the hematological cancer candidate Cantrixil and the veterinary reformulation Paccal Vet—to clinical proof-of-concept before out-licensing. Recent corporate actions, such as a proposed reverse share split, indicate efforts to stabilize its financial structure while progressing key preclinical and clinical studies.

Therapeutic Areas